Stay Updated with the Latest Tenon Medical, Inc. TNON News in Real Time
Find TNON news now at Meyka AI. Stay informed with the latest Tenon Medical, Inc. stocks updates, including price news, market analysis, and expert insights.
Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21
Moderna stock jumps 122% after announcing its personalized mRNA melanoma vaccine met Phase 3 trial goals. The vaccine reduced cancer recurrence and spread when combined with Merck’s Keytruda.
Hays Stock Rises 0.52% as Recruiter Cuts Dividend 65% Amid Hiring Slump
Hays stock edged up 0.52% on August 20, 2026, after the recruitment giant posted FY26 results. The company cut its total annual dividend by 65%, from 1.24 pence to 0.44 pence per share. Net fees fell as hiring activity stayed weak across Hays’ key markets. Investors focused on cost cuts and stabilizing margins rather than…
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20
Moderna jumps 177% and Merck rises 12% after their mRNA cancer vaccine meets Phase 3 endpoints for melanoma. The combo reduced cancer recurrence and spread in over 1,100 patients.
Crypto Prices Today: Bitcoin Hits $69,551, Ethereum Gains 17.74% as Hyperliquid Surges 20.97%
Crypto prices surged sharply on Thursday, August 20, 2026, breaking weeks of sideways trading. Bitcoin jumped to $69,551, gaining roughly 8% in 24 hours. Ethereum climbed 17.74% to reclaim the $2,000 level, while Hyperliquid’s HYPE token surged 20.97%. The rally followed a surprise US Treasury announcement to double its long-dated bond buyback operations. Total crypto…
NVDA Stock, AMD Stock, Micron and Broadcom Gain as AI Spending Estimates Rise
AI spending estimates are rising again, giving semiconductor stocks a fresh boost. On August 7, 2026, Goldman Sachs estimated global AI investment could reach about $1 trillion this year, above widely cited hyperscaler spending forecasts. That outlook is supporting demand for AI chips, memory and networking hardware. As a result, NVDA stock, AMD stock, Micron…
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.
Pentagon Orders 30 U.S. Universities to Audit China Research Ties by August 31
Pentagon orders 30 U.S. universities to audit foreign research ties, mainly Chinese institutions, by August 31 or lose federal funding eligibility. Harvard, MIT, and Johns Hopkins among those affected.
Moderna Soars 177% After Melanoma Vaccine Clears Late-Stage Trial on August 19
Moderna jumps 177% and Merck gains 12% after their personalized mRNA cancer vaccine met key goals in a Phase 3 melanoma trial, the first positive late-stage result for an mRNA cancer therapy.